GLP-1 Receptor Agonist [EPC]

188226 reported adverse events

Drugs of this class: SEMAGLUTIDE LIRAGLUTIDE DULAGLUTIDE EXENATIDE (INSULIN DEGLUDEC AND LIRAGLUTIDE) INSULIN GLARGINE AND LIXISENATIDE LIXISENATIDE ORAL SEMAGLUTIDE

These side effects are most commonly reported by patients taking drugs of the GLP-1 Receptor Agonist [EPC] class:

# Side effect Count
0 BLOOD GLUCOSE INCREASED 29368
1 NAUSEA 29287
2 WEIGHT DECREASED 19269
3 INJECTION SITE PAIN 13138
4 VOMITING 12667
5 DIARRHOEA 11296
6 DECREASED APPETITE 11195
7 INJECTION SITE HAEMORRHAGE 8804
8 BLOOD GLUCOSE DECREASED 8797
9 HEADACHE 6196
See all common reactions for GLP-1 Receptor Agonist [EPC]

Drugs of the GLP-1 Receptor Agonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EARLY SATIETY 689 0.4838
1 MEDULLARY THYROID CANCER 79 0.4072
2 INJECTION SITE NODULE 3023 0.3464
3 DRUG DELIVERY SYSTEM ISSUE 277 0.3378
4 GLYCOSYLATED HAEMOGLOBIN ABNORMAL 160 0.3306
5 INTENTIONAL DEVICE MISUSE 1206 0.3184
6 ACCIDENTAL UNDERDOSE 1672 0.2996
7 INJECTION SITE EXTRAVASATION 3062 0.2756
8 GLYCOSYLATED HAEMOGLOBIN DECREASED 267 0.2713
9 NEEDLE TRACK MARKS 64 0.2540
See all enriched reactions for GLP-1 Receptor Agonist [EPC]